Existing therapies for JIA include nonselective nonsteroidal antiinflammatory drugs, which have been shown to antagonize platelet function, and escalation to biologic therapies including anti–tumor necrosis factor (e.g., infliximab, adalimumab, and golimumab), anti–IL‐6 (tocilizumab), and anti–IL‐1 (canakinumab and anakinra) (43). Here, IL6 is linked to juvenile idiopathic arthritis.